Executive Summary
In the BSE PHARMA sector, Q4 FY26 earnings highlight robust growth led by Lupin with 32% YoY revenue and 68% EBITDA surge, contrasting Biocon's milder 10% revenue growth ex-one-time items, signaling US and biosimilars as key drivers amid mixed India performance.
Aggregate revenue growth across reporting firms averages ~21% YoY in Q4 (Lupin 32%, Biocon 10%), with EBITDA margins expanding sharply (Lupin gross to 75% from 61.7% YoY, Biocon generics +300 bps QoQ). Aurobindo schedules earnings on May 22, 2026, kicking off catalyst season, while Sun Pharma's promoter reclassification of 1.80% shares to public could enhance free float. Sector themes include outperformance in US sales (Lupin +40% YoY) and biosimilars (Biocon +12% YoY), but CRDMO flatness at Biocon and modest India FY growth (Lupin +7.1%) flag domestic pressures. No capital allocation or insider trades noted beyond reclass, with forward pipelines (Lupin 50+ US launches) building multi-year alpha. Overall, mixed sentiment prevails, but Lupin emerges as top performer, warranting overweight amid earnings momentum.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate governance
Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from May 13, 2026.
Investment Signals (11)
- Lupin ↓ (BULLISH)▲
Q4 revenue +32% YoY to ₹7,475 Cr, EBITDA +68% YoY to ₹2,171 Cr, US sales +40% YoY to USD 1,318 Mn
- Lupin ↓ (BULLISH)▲
FY26 revenue +23% YoY to ₹27,958 Cr, EBITDA +55% YoY to ₹8,160 Cr, gross margins expanded to 75% from 61.7% YoY
- Biocon ↓ (BULLISH)▲
Q4 biosimilars revenue +12% YoY to ₹2,756 Cr, EBITDA +33% YoY to ₹720 Cr, R&D at 7% of revenues signaling innovation push
- Biocon ↓ (BULLISH)▲
Adjusted Q4 EBITDA +29% YoY with 23% margin, FY26 EBITDA +25% YoY, generics margins +300 bps QoQ to 8%
- Sun Pharma ↓ (BULLISH)▲
Promoter group reclassification of 4.31 Cr shares (1.80% total) to public category, potentially increasing free float and liquidity
- Lupin ↓ (BULLISH)▲
Filed 11 US products, launched 15 in FY26, pipeline of 50+ launches (10 FTFF, 4 biosimilars) over next 3 years
- Biocon ↓ (BULLISH)▲
Syngene GCP NABL accreditation in Q4 FY26, enhancing CRDMO credibility despite flat 2% YoY growth
- Lupin ↓ (BULLISH)▲
India chronic share +200 bps to 66% FY26 (target 70% in 5 years), Q4 prescriptions +14.5% vs IPM +11.6%
- Aurobindo ↓ (BULLISH)▲
Earnings call May 22, 2026, for Q4 FY26 results, opportunity to confirm sector growth trends
- Lupin vs Biocon▲
Lupin Q4 revenue growth 32% YoY outperforms Biocon's 10% ex-len, EBITDA growth 68% vs 29% adj [BULLISH for Lupin relative]
- Biocon ↓ (NEUTRAL-BULLISH)▲
FY26 group revenue +13% YoY ex-len, CRDMO flat at 3% but biosimilars driving overall momentum
Risk Flags (8)
- Biocon/CRDMO↓ [MEDIUM RISK]▼
Q4 growth only 2% YoY to ₹1,037 Cr, FY26 flat at 3% YoY to ₹3,739 Cr despite biosimilars strength
- Lupin/India↓ [MEDIUM RISK]▼
FY26 formulations growth modest +7.1% YoY, diabetes segment +9.4% vs category +12.2% underperformance
- Lupin/OpEx↓ [MEDIUM RISK]▼
Employee expenses +24.1% YoY in Q4, other operating income -21% YoY to ₹83 Cr pressuring profitability
- Biocon/Net Profit↓ [MEDIUM RISK]▼
Q4 reported net profit ₹179 Cr despite EBITDA gains, highlighting one-time impacts and ex-len adjustments
- Sun Pharma/Promoter↓ [LOW-MEDIUM RISK]▼
Reclassification requests from key promoters (Sudhir Valia 0.60%, Raksha Valia 1.20%) totaling 1.80%, potential signal of reduced control
- Biocon vs Lupin▼
Biocon Q4 revenue growth 10% YoY ex-len lags Lupin's 32%, CRDMO weakness vs Lupin EM +49% Q4 [RELATIVE RISK for Biocon]
- Lupin/Guidance Absence↓ [LOW RISK]▼
No explicit FY27 guidance despite strong FY26, watch for earnings call clarity on India slowdown
- Sector/India Domestic [SECTOR RISK]▼
Both Lupin Q4 +11.5% and Biocon generics muted vs US/EM strength, IPM competition pressuring prescriptions
Opportunities (9)
- Lupin/US Pipeline↓ (OPPORTUNITY)◆
50+ launches next 3 years including 10 exclusive FTFF, 4 biosimilars, building on FY26 15 launches/11 filings
- Lupin/India Chronic↓ (OPPORTUNITY)◆
Share to 70% in 5 years from 66%, pipeline 80+ new launches, Q4 outperformance vs IPM
- Biocon/Biosimilars↓ (OPPORTUNITY)◆
+12% YoY Q4 to ₹2,756 Cr, +33% EBITDA, R&D 7% of revenues for sustained leadership
- Biocon/Syngene↓ (OPPORTUNITY)◆
GCP NABL accreditation boosts CRDMO turnaround potential despite flat growth
- Sun Pharma/Reclass↓ (OPPORTUNITY)◆
1.80% shares to public enhances index eligibility, liquidity; board approval pending
- Aurobindo/Earnings↓ (OPPORTUNITY)◆
May 22, 2026 call for Q4 FY26 results, potential to match Lupin/Biocon growth trends
- Lupin/EM Growth↓ (OPPORTUNITY)◆
Q4 +49% YoY, complementing US +40%, diversifying from India modest FY +7.1%
- Biocon/Generics Margins↓ (OPPORTUNITY)◆
+300 bps QoQ to 8% in Q4, +13% YoY ex-len revenue, margin expansion play
- Sector/US Focus (OPPORTUNITY)◆
Lupin +40% YoY leads, pair with Biocon biosimilars for US/ex-US alpha
Sector Themes (6)
- Explosive EBITDA Growth (BULLISH IMPLICATION)◆
Lupin +68% Q4/+55% FY26 YoY, Biocon +29% adj Q4/+25% FY26, driven by US/biosimilars; implies leverage from scale
- US & EM Outperformance (STRATEGIC SHIFT)◆
Lupin US +40% FY26/USD 1,318 Mn, EM +49% Q4; contrasts India FY +7.1%, highlighting export reliance
- Margin Expansion Trends (POSITIVE)◆
Lupin gross to 75% (+13.3 pts YoY), Biocon generics +300 bps QoQ; sector avg gross/margins improving despite OpEx rises
- Pipeline Build-Up (CATALYST RICH)◆
Lupin 50+ US/80+ India launches, Biocon R&D 7%; multi-year revenue visibility in biosimilars/chronic therapies
- Mixed Domestic Momentum (CAUTION)◆
Lupin India Q4 +11.5% (chronic +2 pts share) vs FY +7.1%, Biocon generics +13% ex-len; competition caps upside
- CRDMO Weakness (WATCH AREA)◆
Biocon flat 2-3% YoY, potential sector drag unless accreditations like Syngene unlock deals
Watch List (8)
-
Q4 FY26 results discussion May 22, 2026 at 8:30 AM IST; pre-register for insights on sector trends matching Lupin/Biocon
-
Monitor FY27 outlook on chronic 70% share target, diabetes recovery post FY26 underperformance
-
Flat growth trajectory; watch Q1 FY27 for Syngene accreditation impact on deals post-Q4 NABL
-
Promoter reclass of 1.80% shares; track board decision timeline for free float implications
-
50+ pipeline execution, esp. 10 FTFF/4 biosimilars over next 3 years; next filings/launches
-
Sustained +12% YoY momentum and 7% R&D; Q1 FY27 for EBITDA margin continuity at 23%
- Sector/Earnings Season👁
Aurobindo May 22 as lead; compare Lupin 32%/Biocon 10% Q4 growth for peers
-
Post-reclass holdings (Sudhir 0.60%, Raksha 1.20%); any further stake changes
Filing Analyses
(4)
14-05-2026
Aurobindo Pharma Limited announced an Earnings Call scheduled for May 22, 2026, at 8:30 AM IST to discuss the Audited Financial Results for Q4 FY26 and the full year ended March 31, 2026. Participants can join via Zoom by pre-registering at the provided link, with the Earnings Presentation to be available on the company's website post-results announcement. This notice complies with Regulation 30(2) of SEBI (LODR) Regulations, 2015.
- · Zoom pre-registration link: http://bit.ly/42COVL4
- · Company codes: AUROPHARMA (NSE), 524804 (BSE)
14-05-2026
Biocon Limited reported Q4 FY26 group operating revenue growth of 10% YoY excluding one-time generic lenalidomide, driven by 12% YoY biosimilars growth to ₹2,756 Cr and 13% YoY generics growth (ex-len) to ₹847 Cr, while CRDMO grew only 2% YoY to ₹1,037 Cr. EBITDA reached ₹1,073 Cr (23% margin, adjusted +29% YoY), with biosimilars EBITDA at ₹720 Cr (+33% YoY), but reported net profit was ₹179 Cr. For FY26 adjusted, revenues and EBITDA grew 13% and 25% respectively, though CRDMO full-year growth was flat at 3% YoY to ₹3,739 Cr.
- · Biosimilars R&D investments at 7% of revenues in Q4 FY26.
- · Generics EBITDA margins improved nearly 300 bps over Q3 FY26 to 8%.
- · Syngene obtained GCP NABL accreditation in Q4 FY26.
- · Syngene CRDMO EBITDA margin at 25% for FY26.
- · Health Canada approvals for Bosaya™ and Vevzuo™; U.S. FDA approval for liraglutide; U.S. commercial launches of Bosaya™ and Aukelso™ post-quarter.
14-05-2026
Lupin Limited reported record Q4 FY26 revenue from operations of ₹7,475 Cr, up 32% YoY, and EBITDA of ₹2,171 Cr, up 68% YoY, while FY26 revenue reached ₹27,958 Cr (+23% YoY) and EBITDA ₹8,160 Cr (+55% YoY), driven by US sales of USD 1,318 Mn (+40% YoY) and strong Emerging Markets growth of 49% in Q4. India formulations grew 11.5% YoY in Q4 (prescriptions +14.5% vs IPM +11.6%) but FY growth was modest at 7.1% with diabetes segment underperforming category at 9.4% vs 12.2%. Other positives include gross margins at 75% in Q4 (up from 61.7% YoY), however other operating income declined 21% YoY to ₹83 Cr and employee expenses rose 24.1% YoY.
- · Filed 11 products and launched 15 in US FY26; pipeline of 50+ launches in next 3 years including 10 exclusive first-to-files, 4 biosimilars, 2-3 505(b)(2)s.
- · India chronic segment share increased to 66% from 64% in FY25; target 70% in next 5 years.
- · Pipeline of 80+ new product launches in India over coming years.
- · R&D spend 8% of sales in Q4 FY26.
- · USFDA issued EIR for Goa and VAI status during quarter.
- · FY27 guidance: high-single digit top-line growth, margins around 25%.
14-05-2026
Sun Pharmaceutical Industries Limited received requests on May 14, 2026, from Promoter Group members Mr. Sudhir Vrundavandas Valia (1,43,45,019 shares, 0.60%), Mrs. Raksha Sudhir Valia (2,88,30,352 shares, 1.20%), and Mrs. Krishna Vrundavandas Valia (0 shares, 0%) for reclassification to 'Public' category under Regulation 31A of SEBI (LODR) Regulations, 2015. The total shares involved are 4,31,75,371, representing 1.80% of the company's shares. The requests will be examined by the company and placed before the Board for approval in due course.
- · Scrip Symbol: SUNPHARMA; Scrip Code: 524715
- · CIN: L24230GJ1993PLC019050
Get daily alerts with 11 investment signals, 8 risk alerts, 9 opportunities and full AI analysis of all 4 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Pharma Sector Regulatory Filings
🇮🇳 More from India
View all →May 28, 2026
India Pre-Market Regulatory Roundup — May 28, 2026
India Pre-Market Regulatory Roundup
May 28, 2026
India Quarterly Results BSE NSE Announcements — May 28, 2026
India Quarterly Results BSE NSE Announcements
May 28, 2026
India Upcoming Corporate Actions BSE NSE — May 28, 2026
India Upcoming Corporate Actions BSE NSE
May 27, 2026
India Pre-Market Regulatory Roundup — May 27, 2026
India Pre-Market Regulatory Roundup